Pancreatic Cancer Research

ResearcherCedars-Sinai Medical CenterActive in the last 2 years

Nicholas N. Nissen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0003-1078-091X; OpenAlex author ID A5022975542, A5110455929. Sources: OpenAlex.

Their work

Papers
24 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
62
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: 3 papers · 2018: none · 2019: 2 papers · 2020: none · 2021: 3 papers · 2022: 3 papers · 2023: 3 papers · 2024: 4 papers · 2025: 2 papers

Papers 24

  1. Enhancing management of pancreatic cancer: impact of a same day multidisciplinary clinic on access to guideline-directed care. Co-author DOI 10.1016/j.hpb.2025.07.012↗
  2. Circulating tumor cell and oncosome subtypes in portal and peripheral venous circulations may be used for diagnosis and prognostication of pancreatic cancer. Co-author DOI 10.1038/s41698-025-01165-4↗
  3. Patterns of Failure in Patients With Borderline Resectable/Locally Advanced Pancreatic Cancer After Preoperative Chemotherapy and Stereotactic Body Radiation T… Co-author DOI 10.1016/j.adro.2024.101471↗
  4. Cancer-related cells and oncosomes in the liquid biopsy of pancreatic cancer patients undergoing surgery. Co-author DOI 10.1038/s41698-024-00521-0↗
  5. Ascites Is a Poor Prognostic Factor in Advanced Pancreatic Adenocarcinoma and May Be Undertreated: A Prospective Cohort Study. Co-author DOI 10.14309/ctg.0000000000000719↗
  6. The Disproportionate Rise in Pancreatic Cancer in Younger Women Is Due to a Rise in Adenocarcinoma and Not Neuroendocrine Tumors: A Nationwide Time-Trend Analy… Co-author DOI 10.3390/cancers16050971↗
  7. Increasing Pancreatic Cancer Incidence in Young Women in the United States: A Population-Based Time-Trend Analysis, 2001-2018. Co-author DOI 10.1053/j.gastro.2023.01.022↗
  8. Management of Patients With Pancreatic Cancer Using the "Right Track" Model. Co-author DOI 10.1093/oncolo/oyad080↗
  9. Pancreatic Cancer Incidence Trends by Race, Ethnicity, Age and Sex in the United States: A Population-Based Study, 2000-2018. Co-author DOI 10.3390/cancers15030870↗
  10. Hyaluronan heterogeneity in pancreatic ductal adenocarcinoma: Primary tumors compared to sites of metastasis. Co-author DOI 10.1016/j.pan.2021.09.015↗
  11. A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable … First author DOI 10.1097/sla.0000000000004669↗
  12. Circulating Fatty Objects and Their Preferential Presence in Pancreatic Cancer Patient Blood Samples. First author DOI 10.3389/fphys.2022.827531↗
  13. Incidence of Pancreatic Cancer by Age and Sex in the US, 2000-2018. Co-author DOI 10.1001/jama.2021.18859↗
  14. Feasibility and efficacy of enteral tube feeding on weight stability, lean body mass, and patient-reported outcomes in pancreatic cancer cachexia. Co-author DOI 10.1002/jcsm.12799↗
  15. Epithelial cell transforming 2 is regulated by Yes-associated protein 1 and mediates pancreatic cancer progression and metastasis. Co-author DOI 10.1152/ajpgi.00185.2020↗
  16. A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2018.12.060↗
  17. MSP-RON Signaling Is Activated in the Transition From Pancreatic Intraepithelial Neoplasia (PanIN) to Pancreatic Ductal Adenocarcinoma (PDAC). Co-author DOI 10.3389/fphys.2019.00147↗
  18. Anaplastic Lymphoma Kinase Rearrangement and Response to Crizotinib in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1200/po.17.00016↗
  19. Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant Therapy. First author DOI 10.1245/s10434-017-6076-z↗
  20. Identifying prognostic intratumor heterogeneity using pre- and post-radiotherapy 18F-FDG PET images for pancreatic cancer patients. Co-author DOI 10.21037/jgo.2016.12.04↗
  21. Influence of Body Mass Index and Albumin on Perioperative Morbidity and Clinical Outcomes in Resected Pancreatic Adenocarcinoma. Co-author DOI 10.1371/journal.pone.0152172↗
  22. Impact of margin status and lymphadenectomy on clinical outcomes in resected pancreatic adenocarcinoma: implications for adjuvant radiotherapy. Co-author DOI 10.3978/j.issn.2078-6891.2015.109↗
  23. Dosimetric evaluation of simultaneous integrated boost during stereotactic body radiation therapy for pancreatic cancer. Co-author DOI 10.1016/j.meddos.2014.09.001↗
  24. Pancreatic cancer cachexia: a review of mechanisms and therapeutics. Co-author DOI 10.3389/fphys.2014.00088↗

Closest collaborators

The 25 strongest of 62 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andrew Eugene Hendifar · 16 shared papers, 2014–2025 · strength 1.94
  2. Simon K. Lo · 13 shared papers, 2014–2025 · strength 1.88
  3. Arsen Osipov · 14 shared papers, 2016–2025 · strength 1.84
  4. Stephen Jacob Pandol · 12 shared papers, 2014–2025 · strength 1.77
  5. Srinivas Gaddam · 7 shared papers, 2021–2025 · strength 1.23
  6. Jun Gong · 7 shared papers, 2021–2025 · strength 1.19
  7. Brent K. Larson · 4 shared papers, 2022–2025 · strength 0.65
  8. Yazan Abboud · 4 shared papers, 2021–2024 · strength 0.62
  9. Rabindra R. Watson · 3 shared papers, 2023–2025 · strength 0.52
  10. Richard Tuli · 8 shared papers, 2014–2019 · strength 0.50
  11. Debiao Li · 3 shared papers, 2023–2024 · strength 0.47
  12. Jamil S. Samaan · 3 shared papers, 2021–2023 · strength 0.43
  13. Stephanie N. Shishido · 2 shared papers, 2024–2025 · strength 0.43
  14. Peter Kühn · 2 shared papers, 2024–2025 · strength 0.43
  15. Abrahm Levi · 2 shared papers, 2024–2025 · strength 0.39
  16. Alexandra Gangi · 2 shared papers, 2024–2025 · strength 0.39
  17. Mitchell R. Kamrava · 2 shared papers, 2024–2025 · strength 0.39
  18. Veronica Placencio-Hickok · 3 shared papers, 2019–2022 · strength 0.33
  19. Qiang Wang · 2 shared papers, 2019–2021 · strength 0.21
  20. Ce Li · 2 shared papers, 2019–2021 · strength 0.21
  21. Justin Wang · 1 shared paper, 2024 · strength 0.21
  22. Eric M. Chung · 1 shared paper, 2024 · strength 0.20
  23. Marc A. Attiyeh · 1 shared paper, 2024 · strength 0.20
  24. Matthew Ebia · 1 shared paper, 2025 · strength 0.19
  25. Cristina Rosa Ferrone · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.